Table 2.
Use of herbs for symptoms associated with anxiety and depression during the Covid- 19 pandemic among Mexican population.
| Medicinal plants contained in products | Citrus × aurantium [SLPM 46949], N = 524 (%) |
Matricaria chamomilla [SLPM 10445] N = 508 |
Valeriana sorbifolia [SLPM 40223] N = 419 |
Tilia mexicana [SLPM 32890] N = 360 |
Passiflora edulis [SLPM 32890] N = 353 |
Cinnamomum verum [SLPM 39788] N = 171 |
Ginkgo biloba [SLPM 10408] N = 153 |
Agastache mexicana [SLPM 39750] N = 134 | Macrosiphonia hypoleuca [SLPM 44477] N = 110 | Aloysia citrodora (SLPM 37141) N = 90 | Cannabis sativa [SLPM 3802] N = 44 | Unidentified N = 194 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <1 month | 170 (32.4) | 166 (32.7) | 112 (26.7) | 88 (24.4) | 104 (29.5) | 44 (25.7) | 38 (24.8) | 25 (18.7) | 15 (13.6) | 20 (22.2) | 5 (11.4) | 46 (23.7) |
| 1–3 months | 143 (27.3) | 123 (24.2) | 127 (30.3) | 106 (29.4) | 100 (28.3) | 49 (28.7) | 35 (22.9) | 35 (26.1) | 29 (26.4) | 20 (22.2) | 7 (15.9) | 73 (37.6) |
| 3–6 months | 75 (14.3) | 76 (15) | 55 (13.1) | 47 (13.1) | 43 (12.2) | 27 (15.8) | 22 (14.4) | 16 (11.9) | 20 (18.2) | 13 (14.4) | 10 (22.7) | 30 (15.5) |
| 6–12 months | 65 (12.4) | 64 (12.6) | 60 (14.3) | 50 (13.9) | 47 (13.3) | 21 (12.3) | 28 (18.3) | 25 (18.7) | 26 (23.6) | 15 (16.7) | 6 (13.6) | 21 (10.8) |
| >12 months | 71 (13.5) | 79 (15.6) | 65 (15.5) | 69 (19.2) | 59 (16.7) | 30 (17.5) | 30 (19.6) | 33 (24.6) | 20 (18.2) | 22 (24.4) | 16 (36.4) | 24 (12.4) |
| Relative/friend | 321 (61.3) | 296 (58.3) | 252 (60.1) | 219 (60.8) | 197 (55.8) | 102 (59.6) | 82 (53.6) | 83 (61.9) | 57 (51.8) | 49 (54.4) | 27 (61.4) | 114 (58.8) |
| Own initiative | 140 (26.7) | 158 (31.1) | 106 (25.3) | 96 (26.7) | 104 (29.5) | 43 (25.1) | 43 (28.1) | 33 (24.6) | 29 (26.4) | 27 (30) | 13 (29.5) | 51 (26.3) |
| Media | 33 (6.3) | 30 (5.9) | 22 (53) | 15 (4.2) | 17 (4.8) | 15 (8.8) | 8 (5.2) | 7 (5.2) | 9 (8.2) | 5 (5.6) | 0 | 15 (7.7) |
| Herbalist | 29 (5.5) | 24 (4.7) | 38 (9.1) | 30 (8.3) | 33 (9.3) | 11 (6.4) | 20 (13.1) | 11 (8.2) | 15 (13.6) | 9 (10) | 4 (9.1) | 14 (7.2) |
| Deterioration | 5 (1) | 2 (0.4) | 5 (1.2) | 4 (1.1) | 5 (1.4) | 3 (1.8) | 1 (0.7) | 3 (2.2) | 3 (2.7) | 3 (3.3) | 1 (2.3) | 2 (1) |
| Improvement | 344 (65.6) | 324 (63.8) | 295 (70.4) | 253 (70.3) | 242 (68.6) | 115 (67.3) | 110 (71.9) | 95 (70.9) | 89 (80.9) | 59 (65.6) | 36 (81.8) | 137 (70.6) |
| No effect | 175 (33.4) | 182 (35.8) | 119 (28.4) | 103 (28.6) | 106 (30) | 53 (31) | 42 (27.5) | 36 (26.9) | 18 (16.4) | 28 (31.1) | 7 (15.9) | 55 (28.4) |
| Concomitant use with | ||||||||||||
| Another plant | 431 (82.3) | 417 (82.1) | 361 (86.2) | 344 (95.6) | 317 (89.8) | 106 (62) | 102 (66.7) | 130 (97) | 93 (84.5) | 77 (85.6) | 13 (29.5) | 165 (85.1) |
| Allopathic drug | 157 (30) | 112 (22) | 127 (30.3) | 105 (29.2) | 107 (30.3) | 48 (28.1) | 45 (29.4) | 42 (31.3) | 32 (29.1) | 21 (23.3) | 13 (29.5) | 51 (26.3) |